Compare Abbott Laboratories (ABT) vs Anheuser-Busch Inbev SA (BUD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Anheuser-Busch Inbev SA — how do they compare? Abbott Laboratories trades at $95.8 (market cap $166.94B), while Anheuser-Busch Inbev SA trades at $79.53 (market cap $155.34B). The key difference: Abbott Laboratories and Anheuser-Busch Inbev SA are close in size by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | BUD | |
|---|---|---|
Market Cap | $166.94B | $155.34B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $85.09 |
52-Week Low | $82.57 | $57.10 |
Enterprise Value | $193.69B | $216.53B |
Dividend Yield | 2.63% | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
BUD trades at $79.74, down 1.95% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, maintains healthy profit margins (net income margin 11.9%), and shows improving cash flow trends. Recent news highlights premiumization strategies and digital expansion efforts to drive growth amid changing consumer preferences in the beverage-alcohol industry.
The outlook remains positive with analyst consensus pointing to 13% upside to the $90.08 price target. Key opportunities include continued earnings momentum and dividend yield support, while risks involve alcohol consumption trends and competitive pressures. The stock presents a compelling value proposition for investors seeking stable returns with moderate growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →
